GSK announced on February 24 its third acquisition of 2026 with the purchase of 35Pharma Inc., a clinical-stage biopharmaceutical company. The purchase price is $950 million CAD (approximately $693 million USD). Based in Montreal, Canada, 35Pharma develops novel transforming growth factor-beta superfamily therapeutics. 35Pharma’s lead candidate, HS235, is being developed for the […]
The post GSK Announces Third Acquisition of the Year appeared first on LevinPro Healthcare M&A – The latest healthcare M&A news.
